| |
|
|
| |
| 投稿时间： 2015-11-18 最后修改时间： 2015-12-04 摘要点击次数: 2524 全文下载次数: 1726 |
| |
| 引用本文：陈晔, 孙静, 赵红艳,等.金砖国家艾滋病抗病毒治疗药物保障策略及启示[J].中国卫生政策研究,2016,9(2):45-51 |
|
| 陈晔, 孙静, 赵红艳, 杨婷婷, 马丽平 |
| 国家卫生计生委医院管理研究所 北京 100191 |
| |
|
| | 摘要:随着艾滋病免费抗病毒治疗政策的推行,免费治疗人数的增加,药品治疗费用的攀升,金砖五国的艾滋病抗病毒药物保障均面临巨大挑战。为此,金砖五国推出了一系列政策以促进药物国产化和压低进口药品价格。本文对金砖国家艾滋病流行及防治情况、防艾药物的生产供给情况及药物保障政策进行分析,并提出启示与建议:(1)建立艾滋病抗病毒治疗药物统筹协调机制;(2)减少药品专利许可,增加国产药物仿制的可能;(3)与原研企业谈判获得自愿许可或技术转让加快药物国产化进程;(4)利用反垄断法获得药品自愿许可促进药品国产化;(5)必要时启动强制许可实现药品国产化;(6)寻求多种谈判筹码降低进口药品价格;(7)加强非政府组织自身能力建设。 | |
|
|
关键词:金砖国家 艾滋病 药物保障策略
|
| |
| BRICS AIDS medicines and antiretroviral therapy protection strategy and implications for China |
| CHEN Ye, SUN Jing, ZHAO Hong-yan, YANG Ting-ting, MA Li-ping |
| Institute of Hospital Administration, Chinese National Institute of Health, Beijing 100191, China |
| |
|
| | Abstract:BRICS has been dealing with the problem of increase in the number of the patients who require antiretroviral therapy and this therapy's price-rise by promoting medicine to domestic production and reducing the imported drug price. This paper reviewed the situation of BRICS HIV epidemic and prevention, anti-retroviral therapy drugs production and supply, drug security policy and strategy, and the following seven recommendations are straight forwarded to China based on the BRICS AIDS antiretroviral treatment coverage strategic comparison:(1) The establishment of an ARV drugs co-ordination mechanism;(2) The reduction of the drug patent licenses while increasing the domestic generic drugs possibility;(3)Negotiations with the original research process of domestic pharmaceutical enterprises to obtain a voluntary license or speed up the technology transfer;(4) The use of antitrust laws to promote access to medicines for a voluntary license pharmacy localization;(5) If necessary, starting the compulsory medicines licensing to achieve localization;(6) Reducing the drug prices by bargain and negotiation; and(7) Strengthening NGO built-in capacity. | |
|
|
|
|
